Clean Yield Speaker Series: Protecting Women’s Access to Health Care Through Advocacy and Corporate Engagement
On April 10 at 2 p.m. EST, Clean Yield will host a webinar on the current state of policies and efforts to protect reproductive rights. The discussion will examine the historical context of this ongoing fight, and explore how corporations and investors can play a role in advancing women’s rights and their access to health care — with a focus on how Clean Yield is involved in the effort.
Liz Levy, Managing Director of Research and Portfolio Manager, will be joined by two prominent leaders in the fight for reproductive justice and women’s empowerment. Judy Norsigian, an internationally recognized author and advocate for women’s health, co-founded Our Bodies Ourselves, an organization dedicated to supporting women, health, and sexuality. Shelley Alpern, Associate Vice President of Corporate Engagement at Rhia Ventures, is an expert in impact investing and shareholder engagement aimed at improving corporate policies and performance on environmental, social, and governance (ESG) matters.
This event has passed.
Clean Yield Speaker Series
“Protecting Women’s Access to Health Care Through Advocacy and Corporate Engagement”
April 10 / Thursday at 2 p.m. EST
Learn More About the Speakers
Shelley Alpern, Associate Vice President of Corporate Engagement, Rhia Ventures
Judy Norsigian, Co-founder, Our Bodies Ourselves
Liz Levy, Managing Director of Research and Portfolio Manager, Clean Yield Asset Management
More News & Insights
Defending Shareholder Voice
Clean Yield has been actively tracking and opposing recent moves by the U.S. Securities and Exchange Commission (SEC) that threaten investors’ long-standing rights to file shareholder proposals under Rule 14a-8.
Charitable Giving: How to Align Philanthropy and Donations with Your Financial Goals
Build Giving to Causes That Are Important to You into Your Financial Planning Philanthropy and charitable donations…
Q2 2026 Market Outlook: Investing in a Time of Dichotomies
A review of the market in Q2 and our plans for the market uncertainties in Q3.